The 3D-PREDICT Study, initiated at the Cancer Institute of Greenville Health System, is a prospective, open-label, multi-institutional, non-interventional study to validate the EV3D assay for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas.
The study will expand to include patients with newly diagnosed high-grade gliomas, high-grade rare tumors and triple negative breast cancer.
According to Kiyatec, the primary objectives of the study are to establish correlation between assay predicted drug response and patient clinical outcomes, and to measure the potential impact of the assay on therapeutic decision-making.
The EV3D assay platform assesses a patient's own cancer cells within a biologically relevant 3D culture microenvironment to provide individualized response prediction to specific therapeutic agents. In this study, the therapeutic agents predicted consist of available, guideline recommended drug options for each cancer type.
Kiyatec's mission is to change the future of cancer care by accurately predicting patient-specific response and non-response before treatment begins by utilizing the patient's own living tumor cells to create functional 3D models to test a battery of cancer therapies.
The goal is to personalize medicine by enabling physicians to isolate only the effective treatments for patients as quickly as possible.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval